Loading…
Trichostatin A Induces Transforming Growth Factor β Type II Receptor Promoter Activity and Acetylation of Sp1 by Recruitment of PCAF/p300 to a Sp1·NF-Y Complex
Transforming growth factor β type II receptor (TβRII) is a tumor suppressor gene that can be transcriptionally silenced by histone deacetylases (HDACs) in cancer cells. In this report, we demonstrated the mechanism by which trichostatin A (TSA), an inhibitor of HDAC, induces the expression of TβR...
Saved in:
Published in: | The Journal of biological chemistry 2005-03, Vol.280 (11), p.10047 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Transforming growth factor β type II receptor (TβRII) is a tumor suppressor gene that can be transcriptionally silenced by
histone deacetylases (HDACs) in cancer cells. In this report, we demonstrated the mechanism by which trichostatin A (TSA),
an inhibitor of HDAC, induces the expression of TβRII in human pancreatic cancer cell lines by modulating the transcriptional
components that bind a specific DNA region of the TβRII promoter. This region of the TβRII promoter possesses Sp1 and NF-Y
binding sites in close proximity (located at â102 and â83, respectively). Treatment of cells with TSA activates the TβRII
promoter in a time-dependent manner through the recruitment of p300 and PCAF into a Sp1·NF-Y·HDAC complex that binds this
DNA element. The recruitment of p300 and PCAF into the complex is associated with a concomitant acetylation of Sp1 and an
overall decrease in the amount of HDAC associated with the complex. Transient overexpression of p300 or PCAF potentiated TSA-induced
TβRII promoter activity. The effect of PCAF was dependent on its histone acetyltransferase activity, whereas that of p300
was independent. Stable transfection of PCAF caused an increase in TβRII mRNA expression, the association of PCAF with TβRII
promoter, and the acetylation of Sp1. Taken together, these results showed that TSA treatment of pancreatic cancer cells leads
to transcriptional activation of the TβRII promoter through modulation of the components of a Sp1·NF-Y·p300·PCAF·HDAC-1 multiprotein
complex. Moreover, the interaction of NF-Y with the Sp1-associated complex may further explain why this specific Sp1 site
mediates transcriptional responsiveness to TSA. |
---|---|
ISSN: | 0021-9258 1083-351X |
DOI: | 10.1074/jbc.M408680200 |